ClinicalTrials.gg
CompletedNCT05526521Updated Nov 25, 2025Results posted

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)

A Phase 3 interventional study of Dupilumab in Chronic Spontaneous Urticaria, sponsored by Sanofi. Completed at 15 sites in 3 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
2 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Chronic Urticaria with a site in United States — 9 open to participants now, 17 under way, 6 of them phase 3. Chronic Urticaria · United States.

Enrollment
50th of 58
15 · median 132
Started
2022
with 4 others
Phase 3
21 of 64
1 open now
Registered
37th of 64
by date
Lead sponsor
3 of 64
Sanofi

Among the 64 studies in Chronic Urticaria with a site in United States, this one is the 50th largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2022, is one of 21 in phase 3, and was the 37th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

9 of the 64 studies in Chronic Urticaria with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 2 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Chronic Urticaria with a site in United States, or all of them as a file.
02

Study summary

This was a multicenter, single-arm, 24-week treatment, Phase 3 study. The purpose of this study was to investigate the PK and safety of dupilumab in children diagnosed with CSU who remain symptomatic despite the use of H1-antihistamine treatment. Study details included: Screening: 2 to 4 weeks; The treatment duration was 24 weeks; Follow-up period: 12 weeks; The study duration was 38 to 40 weeks (including screening and follow-up); The number of study visits was 6.

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥ 2 years to \<12 years of age, at the time of signing the .
  • Participants who had history of a diagnosis of CSU prior to screening (Visit 1) or symptoms consistent with a diagnosis of CSU for at least 3 months in the Investigator's opinion.
  • Participants with CSU (characterized by recurrent itchy wheals with or without angioedema for >6 weeks) who remain symptomatic at the time of screening despite regular H1-antihistamine treatment.
  • Body weight within ≥5 kg to \<60 kg.
  • Participant/parent(s)/caregiver(s)/participant's legally authorized representative, as appropriate, willing and able to comply with study visits and related procedures.

Exclusion criteria

Exclusion Criteria:

Participants were excluded from the study if any of the following criteria apply:

  • Underlying etiology for chronic urticarias other than CSU.
  • Presence of skin morbidities other than CSU that may interfere with the assessment of the study outcomes.
  • Participants with a diagnosis of chronic inducible cold urticaria.
  • Participants with active AD.
  • Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant's participation in the study.
  • Participants with active tuberculosis (TB) or non-tuberculous mycobacterial infection, or a history of incompletely treated.
  • Diagnosed with, suspected of, or at high risk of endoparasitic infection.
  • Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 2 weeks before the screening visit or during the screening period.
  • Known or suspected immunodeficiency.
  • Active or history of malignancy within 5 years before the baseline visit.
  • History of systemic or anaphylaxis to dupilumab including any .
  • Participation in prior dupilumab clinical study or have been treated with commercially available dupilumab.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Dupilumab

    Administered subcutaneously (SC) every 4 weeks (Q4W) or every 2 weeks (Q2W) with or without an initial loading dose based on weight and age

    Drug: Dupilumab

Interventions

  • Injection solution Subcutaneous

    Also known as: Dupixent

06

What researchers measure

Primary outcomes

  1. Serum Concentration of Dupilumab at Weeks 12 and 24

    Blood samples were collected at specified timepoints to obtain dupilumab concentration.

    Time frame: Weeks 12 and 24

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of study intervention, whether or not considered related to study intervention. Serious adverse event (SAE) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was an important medical event. TEAEs were defined as AEs that developed, worsened or became serious during the TE period.

    Time frame: From the first dose of study intervention (Day 1) up to end of follow-up, maximum up to 36 weeks

  2. Number of Participants With Anti-drug Antibodies (ADAs) to Dupilumab

    Blood samples were collected at specified timepoints and ADA samples were assayed using validated methods. Treatment-emergent ADA response was defined as a positive response in the ADA assay post first dose when baseline results were negative or missing. Number of participants with treatment-emergent ADA response is presented.

    Time frame: From the first dose of study intervention (Day 1) up to end of follow-up, maximum up to 36 weeks

  3. Change From Baseline in Children's Dermatology Life Quality Index (C-DLQI) in Participants Aged 4 Years to <12 Years at Week 24

    The C-DLQI assesses impact of skin disease on children's health-related quality of life (HRQoL) over the previous week, contains 10 questions related to symptoms feelings associated with disease, impact of disease on leisure, school or holidays, personal relationships, sleep, and side effects of treatment for the skin disease. All questions were scored on 4-point Likert scale:0 (not at all),1 (a little),2 (a lot),3 (very much). Total C-DLQI was calculated by summing the score of each question and ranged from 0 (no impact) to 30 (severe impact). Higher scores indicated poor HRQoL. Mean is presented. Baseline was defined as closest assessment to first study intervention administration on or prior to Day 1 but no later than Day 4.

    Time frame: Baseline (Day 1) and Week 24

  4. Change From Baseline in Infant's Dermatitis Quality of Life Index (IDQOL) in Participants Aged 2 Years to <4 Years at Week 24

    The IDQOL questionnaire is completed by child's caregiver/guardian with a recall period of 7 days;consists of 10 questions focusing on life quality index (LQI) scored on 4-point Likert scale. An additional question on dermatitis severity is scored on a 5-point Likert scale (0 \[none\] to 4 \[extremely severe\]); it is not considered for calculating total IDQOL. For LQI, score ranges are as follows: Questions 1, 5 to 10: 0 (none) to 3 (all the time/very much). Question 2: 0 (happy), 1 (slightly fretful), 2 (very fretful),3 (always crying). Question 3: 0 (0-15 minutes), 1 (15 minutes-1 hour), 2 (1-2 hours),3 (\>2 hours).Question 4: 0 (\<1 hour), 1 (1-2 hours), 2 (3-4 hours),3 (\>=5 hours). IDQOL total score is the sum of the score of each question of LQI, ranges from 0 (no impact) to 30 (maximum impact). Higher scores indicated poor HRQoL. Mean is presented. Baseline was defined as closest assessment to first study intervention administration on or prior to Day 1 but no later than Day 4.

    Time frame: Baseline (Day 1) and Week 24

  5. Change From Baseline in Modified Urticaria Activity Score Over 7 Days (mUAS7) at Week 24

    A modified version of the UAS (mUAS) was used for the smaller body surface area of child and adolescent participants. The mUAS was derived from the sum of daily hives severity score (HSS) (ranging from 0 to 3 \[0 = absent; 1 = mild {1 to \<10 wheals/24 hours}; 2 = moderate: {10 to 30 wheals/24 hours}; and 3 = intense: {\>30 wheals/24 hours or large confluent areas of wheals}\]) and daily itch severity score (ISS) (ranging from 0 = none to 3 = intense). Daily mUAS total scores range from 0 to 6 (0 to 3 for ISS and 0 to 3 for HSS). Daily mUAS scores were summed over 7-day period to create total score ranging from 0 (no urticaria) to 42 (severe urticaria). Completion of mUAS7 was done by the child or parent(s)/caregiver(s)/legal guardian(s) for participants aged \>=4 years and by parent(s)/caregiver(s) for participants aged \<4 years. Mean is presented. Baseline was defined as sum of the 7 daily measurements obtained within the 7 days prior to first study intervention administration.

    Time frame: Baseline (Day -7 to Day 1) and Week 24

  6. Change From Baseline in Itch Severity Score Over 7 Days (ISS7) at Week 24

    The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. Mean is presented. Baseline was defined as sum of the 7 daily measurements obtained within the 7 days prior to first study intervention administration.

    Time frame: Baseline (Day -7 to Day 1) and Week 24

  7. Change From Baseline in Hive Severity Score Over 7 Days (HSS7) at Week 24

    The HSS7 score is the sum of daily HSS ranging from ranging from 0 to 3 (0 = absent; 1 = mild \[1 to \<10 wheals/24 hours\]; 2 = moderate \[10 to 30 wheals/24 hours\]; and 3 = intense: \[\>30 wheals/24 hours or large confluent areas of wheals\]) recorded by a participant at the same time of each day over 7 days with an overall scale of 0 (no hives) to 21 (severe hives). Higher scores indicate greater intensity of hives. Mean is presented. Baseline was defined as sum of the 7 daily measurements obtained within the 7 days prior to first study intervention administration.

    Time frame: Baseline (Day -7 to Day 1) and Week 24

07

Results

Posted Nov 19, 2025

Participant flow

This study was conducted at 10 sites in Canada, Japan and the United States. A total of 23 participants were screened from 25-Aug-2022 to 02-May-2024 of which 8 were screen failures mainly due to not meeting eligibility criteria.

Participant flow — Overall Study
MilestoneDupilumab 200 mg Q4WDupilumab 300 mg Q4WDupilumab 300 mg Q4W, 600 mg Loading DoseDupilumab 200 mg Q2W, 400 mg Loading Dose
Started1428
Completed1328
Not completed0100
Withdrew: Withdrawal by subject0100

Outcome measures

PrimarySerum Concentration of Dupilumab at Weeks 12 and 24

Blood samples were collected at specified timepoints to obtain dupilumab concentration.

Time frame:
Weeks 12 and 24
Reported as:
Mean · nanogram/milliliter
Serum Concentration of Dupilumab at Weeks 12 and 24
nanogram/milliliterDupilumab 200 mg Q4WDupilumab 300 mg Q4WDupilumab 300 mg Q4W, 600 mg Loading DoseDupilumab 200 mg Q2W, 400 mg Loading Dose
Week 126770010500045800 ± 1240091600 ± 23000
Week 24116000141000 ± 3010051100 ± 2010078500 ± 31600
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of study intervention, whether or not considered related to study intervention. Serious adverse event (SAE) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was an important medical event. TEAEs were defined as AEs that developed, worsened or became serious during the TE period.

Time frame:
From the first dose of study intervention (Day 1) up to end of follow-up, maximum up to 36 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsDupilumab 200 mg Q4WDupilumab 300 mg Q4WDupilumab 300 mg Q4W, 600 mg Loading DoseDupilumab 200 mg Q2W, 400 mg Loading Dose
TEAEs1227
TESAEs0000
SecondaryNumber of Participants With Anti-drug Antibodies (ADAs) to Dupilumab

Blood samples were collected at specified timepoints and ADA samples were assayed using validated methods. Treatment-emergent ADA response was defined as a positive response in the ADA assay post first dose when baseline results were negative or missing. Number of participants with treatment-emergent ADA response is presented.

Time frame:
From the first dose of study intervention (Day 1) up to end of follow-up, maximum up to 36 weeks
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADAs) to Dupilumab
ParticipantsDupilumab 200 mg Q4WDupilumab 300 mg Q4WDupilumab 300 mg Q4W, 600 mg Loading DoseDupilumab 200 mg Q2W, 400 mg Loading Dose
Number of Participants With Anti-drug Antibodies (ADAs) to Dupilumab0000
SecondaryChange From Baseline in Children's Dermatology Life Quality Index (C-DLQI) in Participants Aged 4 Years to <12 Years at Week 24

The C-DLQI assesses impact of skin disease on children's health-related quality of life (HRQoL) over the previous week, contains 10 questions related to symptoms feelings associated with disease, impact of disease on leisure, school or holidays, personal relationships, sleep, and side effects of treatment for the skin disease. All questions were scored on 4-point Likert scale:0 (not at all),1 (a little),2 (a lot),3 (very much). Total C-DLQI was calculated by summing the score of each question and ranged from 0 (no impact) to 30 (severe impact). Higher scores indicated poor HRQoL. Mean is presented. Baseline was defined as closest assessment to first study intervention administration on or prior to Day 1 but no later than Day 4.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · score on a scale
Change From Baseline in Children's Dermatology Life Quality Index (C-DLQI) in Participants Aged 4 Years to <12 Years at Week 24
score on a scaleDupilumab 200 mg Q4WDupilumab 300 mg Q4WDupilumab 300 mg Q4W, 600 mg Loading DoseDupilumab 200 mg Q2W, 400 mg Loading Dose
Change From Baseline in Children's Dermatology Life Quality Index (C-DLQI) in Participants Aged 4 Years to <12 Years at Week 24-3.0-6.0-10.5 ± 3.5-7.3 ± 4.3
SecondaryChange From Baseline in Infant's Dermatitis Quality of Life Index (IDQOL) in Participants Aged 2 Years to <4 Years at Week 24

The IDQOL questionnaire is completed by child's caregiver/guardian with a recall period of 7 days;consists of 10 questions focusing on life quality index (LQI) scored on 4-point Likert scale. An additional question on dermatitis severity is scored on a 5-point Likert scale (0 \[none\] to 4 \[extremely severe\]); it is not considered for calculating total IDQOL. For LQI, score ranges are as follows: Questions 1, 5 to 10: 0 (none) to 3 (all the time/very much). Question 2: 0 (happy), 1 (slightly fretful), 2 (very fretful),3 (always crying). Question 3: 0 (0-15 minutes), 1 (15 minutes-1 hour), 2 (1-2 hours),3 (\>2 hours).Question 4: 0 (\<1 hour), 1 (1-2 hours), 2 (3-4 hours),3 (\>=5 hours). IDQOL total score is the sum of the score of each question of LQI, ranges from 0 (no impact) to 30 (maximum impact). Higher scores indicated poor HRQoL. Mean is presented. Baseline was defined as closest assessment to first study intervention administration on or prior to Day 1 but no later than Day 4.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · score on a scale
Change From Baseline in Infant's Dermatitis Quality of Life Index (IDQOL) in Participants Aged 2 Years to <4 Years at Week 24
score on a scaleDupilumab 200 mg Q4WDupilumab 300 mg Q4WDupilumab 300 mg Q4W, 600 mg Loading DoseDupilumab 200 mg Q2W, 400 mg Loading Dose
Change From Baseline in Infant's Dermatitis Quality of Life Index (IDQOL) in Participants Aged 2 Years to <4 Years at Week 24—-3.0——
SecondaryChange From Baseline in Modified Urticaria Activity Score Over 7 Days (mUAS7) at Week 24

A modified version of the UAS (mUAS) was used for the smaller body surface area of child and adolescent participants. The mUAS was derived from the sum of daily hives severity score (HSS) (ranging from 0 to 3 \[0 = absent; 1 = mild {1 to \<10 wheals/24 hours}; 2 = moderate: {10 to 30 wheals/24 hours}; and 3 = intense: {\>30 wheals/24 hours or large confluent areas of wheals}\]) and daily itch severity score (ISS) (ranging from 0 = none to 3 = intense). Daily mUAS total scores range from 0 to 6 (0 to 3 for ISS and 0 to 3 for HSS). Daily mUAS scores were summed over 7-day period to create total score ranging from 0 (no urticaria) to 42 (severe urticaria). Completion of mUAS7 was done by the child or parent(s)/caregiver(s)/legal guardian(s) for participants aged \>=4 years and by parent(s)/caregiver(s) for participants aged \<4 years. Mean is presented. Baseline was defined as sum of the 7 daily measurements obtained within the 7 days prior to first study intervention administration.

Time frame:
Baseline (Day -7 to Day 1) and Week 24
Reported as:
Mean · score on a scale
Change From Baseline in Modified Urticaria Activity Score Over 7 Days (mUAS7) at Week 24
score on a scaleDupilumab 200 mg Q4WDupilumab 300 mg Q4WDupilumab 300 mg Q4W, 600 mg Loading DoseDupilumab 200 mg Q2W, 400 mg Loading Dose
Change From Baseline in Modified Urticaria Activity Score Over 7 Days (mUAS7) at Week 24-8.0-21.4 ± 1.9-2.8 ± 1.8-7.8 ± 6.6
SecondaryChange From Baseline in Itch Severity Score Over 7 Days (ISS7) at Week 24

The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. Mean is presented. Baseline was defined as sum of the 7 daily measurements obtained within the 7 days prior to first study intervention administration.

Time frame:
Baseline (Day -7 to Day 1) and Week 24
Reported as:
Mean · score on a scale
Change From Baseline in Itch Severity Score Over 7 Days (ISS7) at Week 24
score on a scaleDupilumab 200 mg Q4WDupilumab 300 mg Q4WDupilumab 300 mg Q4W, 600 mg Loading DoseDupilumab 200 mg Q2W, 400 mg Loading Dose
Change From Baseline in Itch Severity Score Over 7 Days (ISS7) at Week 24-5.0-9.6 ± 3.7-1.6 ± 0.6-3.4 ± 3.2
SecondaryChange From Baseline in Hive Severity Score Over 7 Days (HSS7) at Week 24

The HSS7 score is the sum of daily HSS ranging from ranging from 0 to 3 (0 = absent; 1 = mild \[1 to \<10 wheals/24 hours\]; 2 = moderate \[10 to 30 wheals/24 hours\]; and 3 = intense: \[\>30 wheals/24 hours or large confluent areas of wheals\]) recorded by a participant at the same time of each day over 7 days with an overall scale of 0 (no hives) to 21 (severe hives). Higher scores indicate greater intensity of hives. Mean is presented. Baseline was defined as sum of the 7 daily measurements obtained within the 7 days prior to first study intervention administration.

Time frame:
Baseline (Day -7 to Day 1) and Week 24
Reported as:
Mean · score on a scale
Change From Baseline in Hive Severity Score Over 7 Days (HSS7) at Week 24
score on a scaleDupilumab 200 mg Q4WDupilumab 300 mg Q4WDupilumab 300 mg Q4W, 600 mg Loading DoseDupilumab 200 mg Q2W, 400 mg Loading Dose
Change From Baseline in Hive Severity Score Over 7 Days (HSS7) at Week 24-3.0-11.8 ± 1.8-1.2 ± 1.2-4.4 ± 3.6

Adverse events

Collected over From the first dose of study intervention (Day 1) up to end of follow-up, maximum up to 36 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dupilumab 200 mg Q4W0/1 (0%)0/1 (0%)1/1 (100%)
Dupilumab 300 mg Q4W0/4 (0%)0/4 (0%)2/4 (50%)
Dupilumab 300 mg Q4W, 600 mg Loading Dose0/2 (0%)0/2 (0%)2/2 (100%)
Dupilumab 200 mg Q2W, 400 mg Loading Dose0/8 (0%)0/8 (0%)7/8 (87.5%)
Most frequent other events
Showing 10 of 34
Most frequent other events
EventDupilumab 200 mg Q4WDupilumab 300 mg Q4WDupilumab 300 mg Q4W, 600 mg Loading DoseDupilumab 200 mg Q2W, 400 mg Loading Dose
NasopharyngitisInfections and infestations0/10/42/20/8
Viral Upper Respiratory Tract InfectionInfections and infestations1/11/40/22/8
RhinorrhoeaRespiratory, thoracic and mediastinal disorders1/10/40/20/8
Hand-Foot-And-Mouth DiseaseInfections and infestations0/10/41/20/8
HordeolumInfections and infestations0/10/41/20/8
InfluenzaInfections and infestations0/10/41/21/8
Otitis MediaInfections and infestations0/10/41/20/8
Rhinovirus InfectionInfections and infestations0/11/40/20/8
Subcutaneous AbscessInfections and infestations0/11/40/20/8
InsomniaPsychiatric disorders0/11/40/20/8

Baseline characteristics

The safety population included all enrolled participants who took at least 1 dose of the study intervention, regardless of the amount of intervention administered.

Age, Customized
Age, Customized(Participants)Dupilumab 200 mg Q4WDupilumab 300 mg Q4WDupilumab 300 mg Q4W, 600 mg Loading DoseDupilumab 200 mg Q2W, 400 mg Loading DoseTotal
>=2 to <6 years04004
>=6 to <12 years102811
Sex: Female, Male
Sex: Female, Male(Participants)Dupilumab 200 mg Q4WDupilumab 300 mg Q4WDupilumab 300 mg Q4W, 600 mg Loading DoseDupilumab 200 mg Q2W, 400 mg Loading DoseTotal
Female122611
Male02024
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dupilumab 200 mg Q4WDupilumab 300 mg Q4WDupilumab 300 mg Q4W, 600 mg Loading DoseDupilumab 200 mg Q2W, 400 mg Loading DoseTotal
American Indian or Alaska Native00000
Asian10124
Native Hawaiian or Other Pacific Islander00000
Black or African American00011
White04149
More than one race00000
Unknown or Not Reported00011
08

Study locations

15 sites
  • Pediatric Dermatology of Miami Site Number : 8400015
    Coral Gables, Florida 33146, United States
  • Treasure Valley Medical Research Site Number : 8400019
    Boise, Idaho 83706, United States
  • Washington University School of Medicine- Site Number : 8400004
    St Louis, Missouri 63110, United States
  • Boston Childrens Health Physicians Site Number : 8400017
    Hawthorne, New York 10532, United States
  • Columbia University Irving Medical Center Site Number : 8400003
    New York, New York 10032, United States
  • Childrens Hospital Medical Center of Akron- Site Number : 8400020
    Akron, Ohio 44308, United States
  • Cincinnati Children's Hospital Medical Center - PIN- Site Number : 8400001
    Cincinnati, Ohio 45229-3026, United States
  • Vital Prospects Clinical Research Institute, P.C.- Site Number : 8400002
    Tulsa, Oklahoma 74136, United States
  • Monroe Carell Jr. Childrens Hospital at Vanderbilt- Site Number : 8400005
    Nashville, Tennessee 37232, United States
  • Investigational Site Number : 1240009
    Calgary, Alberta T2W 4X9, Canada
  • Investigational Site Number : 1240010
    Edmonton, Alberta T5J 3S9, Canada
  • Investigational Site Number : 1240007
    Hamilton, Ontario L8S1G5, Canada
  • Investigational Site Number : 1240001
    Montreal, Quebec H4A 3J1, Canada
  • Investigational Site Number : 3920001
    Yokohama, Kanagawa 232-8555, Japan
  • Investigational Site Number : 3920002
    Tsu, Mie-ken 514-0125, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Nov 2024, 26 months.

Results were first posted in Nov 2025, 1 year after primary completion.

Of 27 industry-sponsored phase 3 interventional studies under Chronic Urticaria, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 31. This study's 26 months is close to that.

Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 19 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2022
First posted
Sep 2, 2022
StartActual
Aug 25, 2022
Primary completionActual
Nov 11, 2024
CompletionActual
Feb 3, 2025
Results first posted
Nov 19, 2025
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05526521
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 2, 2022
Start date
Aug 25, 2022
Primary completion
Nov 11, 2024
Completion
Feb 3, 2025
Results posted
Nov 19, 2025
Last update
Nov 25, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion